Alignment Healthcare's CEO has sold $2.1 million in shares, prompting discussion about the implications for investors. There are conflicting views on what this sale might mean, with some outlets suggesting it could be a cause for concern, while others downplay its significance and point to other potential risks, such as policy changes. Additionally, the company is facing a whistleblower lawsuit accusing it of accounting fraud, and has recently announced executive leadership updates and been named to the Fortune 1000 list.